Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Depreciation & Amortization (CF) (2018 - 2025)

Bicycle Therapeutics (BCYC) has disclosed Depreciation & Amortization (CF) for 8 consecutive years, with $1.8 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Depreciation & Amortization (CF) fell 19.15% year-over-year to $1.8 million, compared with a TTM value of $6.8 million through Sep 2025, down 4.69%, and an annual FY2024 reading of $7.2 million, up 9.59% over the prior year.
  • Depreciation & Amortization (CF) was $1.8 million for Q3 2025 at Bicycle Therapeutics, up from $1.7 million in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $2.2 million in Q3 2024 and bottomed at $325000.0 in Q1 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $1.3 million, with a median of $1.6 million recorded in 2025.
  • The sharpest move saw Depreciation & Amortization (CF) surged 275.07% in 2022, then fell 19.15% in 2025.
  • Year by year, Depreciation & Amortization (CF) stood at $407000.0 in 2021, then skyrocketed by 240.54% to $1.4 million in 2022, then increased by 19.34% to $1.7 million in 2023, then grew by 3.02% to $1.7 million in 2024, then rose by 3.05% to $1.8 million in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for BCYC at $1.8 million in Q3 2025, $1.7 million in Q2 2025, and $1.6 million in Q1 2025.